Your browser doesn't support javascript.
loading
Control of the HIV-1 Load Varies by Viral Subtype in a Large Cohort of African Adults With Incident HIV-1 Infection.
Price, Matt A; Rida, Wasima; Kilembe, William; Karita, Etienne; Inambao, Mubiana; Ruzagira, Eugene; Kamali, Anatoli; Sanders, Eduard J; Anzala, Omu; Hunter, Eric; Allen, Susan; Edward, Vinodh A; Wall, Kristin M; Tang, Jianming; Fast, Patricia E; Kaleebu, Pontiano; Lakhi, Shabir; Mutua, Gaudensia; Bekker, Linda Gail; Abu-Baker, Ggayi; Tichacek, Amanda; Chetty, Paramesh; Latka, Mary H; Maenetje, Pholo; Makkan, Heeran; Kibengo, Freddie; Priddy, Fran; Gilmour, Jill.
Afiliação
  • Price MA; International AIDS Vaccine Initiative, New York, New York.
  • Rida W; Department of Epidemiology and Biostatistics, University of California-San Francisco.
  • Karita E; Rwanda Zambia HIV Research Group, Lusaka and Ndola.
  • Inambao M; Rwanda Zambia HIV Research Group, Zambia and Kigali.
  • Ruzagira E; Rwanda Zambia HIV Research Group, Rwanda.
  • Kamali A; Rwanda Zambia HIV Research Group, Lusaka and Ndola.
  • Sanders EJ; Rwanda Zambia HIV Research Group, Zambia and Kigali.
  • Anzala O; Rwanda Zambia HIV Research Group, Rwanda.
  • Hunter E; Rwanda Zambia HIV Research Group, Lusaka and Ndola.
  • Allen S; Rwanda Zambia HIV Research Group, Zambia and Kigali.
  • Edward VA; Rwanda Zambia HIV Research Group, Rwanda.
  • Wall KM; MRC/UVRI Uganda Research Unit on AIDS, Entebbe, Uganda.
  • Tang J; International AIDS Vaccine Initiative, New York, New York.
  • Fast PE; Kenyan Medical Research Institute-Wellcome Trust, Kilifi, Nairobi, Kenya.
  • Kaleebu P; Nuffield Department of Clinical Medicine, Centre for Clinical Vaccinology and Tropical Medicine, University of Oxford, Headington, London, United Kingdom.
  • Lakhi S; KAVI Institute of Clinical Research, Nairobi, Kenya.
  • Mutua G; Rwanda Zambia HIV Research Group, Lusaka and Ndola.
  • Bekker LG; Rwanda Zambia HIV Research Group, Zambia and Kigali.
  • Abu-Baker G; Rwanda Zambia HIV Research Group, Rwanda.
  • Tichacek A; Department of Pathology and Laboratory Medicine, Emory University, Atlanta, Georgia.
  • Chetty P; Rwanda Zambia HIV Research Group, Lusaka and Ndola.
  • Latka MH; Rwanda Zambia HIV Research Group, Zambia and Kigali.
  • Maenetje P; Rwanda Zambia HIV Research Group, Rwanda.
  • Makkan H; Department of Pathology and Laboratory Medicine, Emory University, Atlanta, Georgia.
  • Kibengo F; Department of Environmental Health Sciences, Yale School of Public Health, New Haven, Connecticut.
  • Priddy F; The Aurum Institute, South Africa.
  • Gilmour J; School of Pathology, Faculty of Health Sciences, University of the Witwatersrand, South Africa.
J Infect Dis ; 220(3): 432-441, 2019 07 02.
Article em En | MEDLINE | ID: mdl-30938435
ABSTRACT
Few human immunodeficiency virus (HIV)-infected persons can maintain low viral levels without therapeutic intervention. We evaluate predictors of spontaneous control of the viral load (hereafter, "viral control") in a prospective cohort of African adults shortly after HIV infection. Viral control was defined as ≥2 consecutively measured viral loads (VLs) of ≤10 000 copies/mL after the estimated date of infection, followed by at least 4 subsequent measurements for which the VL in at least 75% was ≤10 000 copies/mL in the absence of ART. Multivariable logistic regression characterized predictors of viral control. Of 590 eligible volunteers, 107 (18.1%) experienced viral control, of whom 25 (4.2%) maintained a VL of 51-2000 copies/mL, and 5 (0.8%) sustained a VL of ≤50 copies/mL. The median ART-free follow-up time was 3.3 years (range, 0.3-9.7 years). Factors independently associated with control were HIV-1 subtype A (reference, subtype C; adjusted odds ratio [aOR], 2.1 [95% confidence interval {CI}, 1.3-3.5]), female sex (reference, male sex; aOR, 1.8 [95% CI, 1.1-2.8]), and having HLA class I variant allele B*57 (reference, not having this allele; aOR, 1.9 [95% CI, 1.0-3.6]) in a multivariable model that also controlled for age at the time of infection and baseline CD4+ T-cell count. We observed strong associations between infecting HIV-1 subtype, HLA type, and sex on viral control in this cohort. HIV-1 subtype is important to consider when testing and designing new therapeutic and prevention technologies, including vaccines.
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Tipo de estudo: Prognostic_studies / Risk_factors_studies Idioma: En Revista: J Infect Dis Ano de publicação: 2019 Tipo de documento: Article

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Tipo de estudo: Prognostic_studies / Risk_factors_studies Idioma: En Revista: J Infect Dis Ano de publicação: 2019 Tipo de documento: Article